NovaScan
Private Company
Total funding raised: $2.4M
Overview
NovaScan is a private, pre-revenue diagnostics company pioneering a novel electrical impedance-based platform for rapid, accurate cancer detection. Its primary focus is the development and regulatory clearance of MarginScan™, a device aimed at reducing re-excision rates in surgeries for skin and breast cancer by providing real-time margin assessment. Backed by grant funding, a manufacturing partnership with PHC Group, and a distribution letter of intent with Epredia, NovaScan is targeting its first FDA clearance for skin cancer in early 2027. The company has validated its technology in over 900 patients across multiple cancer types, demonstrating high sensitivity and specificity in clinical studies.
Technology Platform
A cancer detection platform based on measuring the Cole relaxation frequency via spectral bioimpedance, enhanced with AI/ML. This biophysical parameter shifts orders of magnitude in malignant cells, providing a high dynamic range for distinguishing cancerous from non-cancerous tissue.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
NovaScan competes in the intraoperative diagnostics and margin assessment space against established methods like frozen section pathology and newer technologies such as mass spectrometry (e.g., iKnife) and optical imaging systems. Its key differentiator is the claimed high specificity from the Cole frequency measurement and a compact, low-cost form factor designed for point-of-care use without dedicated pathology resources.